SELECT MEDICAL HOLDINGS CORP
Business
SELECT MEDICAL HOLDINGS CORP operates long‑term post‑acute healthcare facilities specializing in care for patients with complex medical and rehabilitation needs. It provides critical illness recovery hospitals certified as LTCHs, inpatient rehabilitation hospitals (IRFs), and outpatient rehabilitation clinics offering physical, occupational, and speech therapy and specialized programs such as ventilator weaning, wound care, pelvic health, and cancer rehabilitation. The company manages three business segments: critical illness recovery hospitals, rehabilitation hospitals, and outpatient rehabilitation, along with corporate and employee‑leasing activities. It operates nationwide across 40 states and the District of Columbia through HIH arrangements, free‑standing hospitals, clinics, and joint ventures with healthcare systems.
Summary from filing dated 2025-02-20
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net income attributable to non-controlling interests | 63 | 73 | 48 | 31 | 48 | |
| Cash dividends declared for common stockholders | −31 | −65 | −64 | −65 | −51 | |
| Issuance of restricted stock | 0 | 0 | 0 | 0 | 0 | |
| Forfeitures of unvested restricted stock | 18,000 | 71,000 | 12,000 | 64,000 | — | |
| Vesting of restricted stock | 17 | 101 | 44 | 36 | 29 | |
| Repurchase of common shares | −101 | −38 | −13 | −196 | −79 | |
| Issuance of non-controlling interests | 16 | 27 | 23 | 10 | 21 | |
| Non-controlling interests acquired in business combination | — | 13 | 9 | 12 | 11 | |
| Distributions to and purchases of non-controlling interests | −73 | −50 | −55 | −38 | −72 | |
| Redemption value adjustment on non-controlling interests | −4,000 | −2 | 2 | 3 | −250 | |
| Concentra Separation and Distribution | — | 209 | — | — | — | |
| Other comprehensive loss | −6 | −43 | −46 | — | — | |
| Other | — | 129,000 | −34,000 | 37,000 | 4,000 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 27 | 60 | 53 | 98 | 74 | |
| Accounts receivable | 864 | 821 | 724 | 941 | 889 | |
| Prepaid income taxes | 20 | 27 | 15 | 32 | 56 | |
| Other current assets | 115 | 112 | 116 | 125 | 120 | |
| Total Current Assets | 1,025 | 1,020 | 1,258 | 1,271 | 1,139 | |
| Operating lease right-of-use assets | 958 | 908 | 791 | 1,170 | 1,079 | |
| Property and equipment, net | 992 | 872 | 845 | — | — | |
| Goodwill | 2,361 | 2,332 | 2,283 | 2,258 | 3,449 | |
| Identifiable intangible assets, net | 101 | 103 | 105 | 352 | 375 | |
| Other assets | 414 | 373 | 368 | 342 | 339 | |
| Total Assets | 5,852 | 5,608 | 7,690 | 7,665 | 7,360 | |
| Overdrafts | 17 | 26 | 30 | 32 | 42 | |
| Current operating lease liabilities | 188 | 180 | 172 | 237 | 229 | |
| Current portion of long-term debt and notes payable | 24 | 20 | 69 | 44 | 18 | |
| Accounts payable | 157 | 142 | 154 | 187 | 234 | |
| Accrued and other liabilities | 598 | 610 | 552 | — | — | |
| Total Current Liabilities | 984 | 978 | 1,248 | 1,155 | 1,273 | |
| Non-current operating lease liabilities | 835 | 787 | 669 | 1,008 | 917 | |
| Long-term debt, net of current portion | 1,804 | 1,692 | 3,584 | 3,835 | 3,556 | |
| Non-current deferred tax liability | 112 | 81 | 120 | 170 | 143 | |
| Other non-current liabilities | 80 | 73 | 83 | 106 | 106 | |
| Total Liabilities | 3,816 | 3,611 | 6,116 | 6,275 | 5,995 | |
| Commitments and contingencies (Note 19) | — | — | — | — | — | |
| Redeemable non-controlling interests | 19 | 10 | 26 | 34 | 39 | |
| Common stock, $0.001 par value, 700,000,000 shares authorized, 128,962,850 and 124,017,191 shares issued and outstanding at 2024 and 2025, respectively | 124,000 | 129,000 | 128,000 | 127,000 | 134,000 | |
| Capital in excess of par | 875 | 911 | 493 | 452 | 504 | |
| Retained earnings | 837 | 770 | 752 | 581 | 593 | |
| Accumulated other comprehensive loss | −6 | 0 | 43 | 89 | 12 | |
| Total Stockholders Equity | 1,706 | 1,681 | 1,288 | 1,122 | 1,110 | |
| Non-controlling interests | 311 | 306 | 259 | 235 | 216 | |
| Total Equity | 2,017 | 1,987 | 1,548 | 1,357 | 1,326 | |
| Total Liabilities and Equity | 5,852 | 5,608 | 7,690 | 7,665 | 7,360 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Distributions from unconsolidated subsidiaries | 53 | 39 | 23 | 22 | 37 | |
| Depreciation and amortization | 140 | 204 | 209 | 206 | — | |
| Provision for expected credit losses | 2 | 4 | 1 | 174,000 | 236,000 | |
| Equity in earnings of unconsolidated subsidiaries | −55 | −60 | −41 | −26 | — | |
| Loss on extinguishment of debt | 0 | 19 | 175,000 | 0 | 0 | |
| (Gain) loss on sale or disposal of assets | 8,000 | −1 | −57,000 | −3 | — | |
| Stock compensation expense | 17 | 101 | 44 | 38 | 31 | |
| Amortization of debt discount, premium and issuance costs | 3 | 3 | 3 | 2 | 2 | |
| Deferred income taxes | 31 | −32 | −16 | 8 | — | |
| Accounts receivable | −45 | −96 | 1 | −52 | 23 | |
| Other current assets | 413,000 | 18 | −29 | −5 | −2 | |
| Other assets | −9 | 13 | 10 | 16 | −7 | |
| Accounts payable | −854,000 | −17 | −6 | −48 | 53 | |
| Accrued expenses | −5 | 26 | 84 | 13 | −73 | |
| Net cash provided by operating activities | 346 | 518 | 582 | 285 | 401 | |
| Business combinations, net of cash acquired | −9 | −13 | −30 | −27 | −82 | |
| Purchases of property, equipment, and other assets | −229 | −222 | −229 | −190 | −181 | |
| Investment in businesses | −1 | 0 | −10 | −17 | −21 | |
| Proceeds from sales and exchanges of assets and sale of business | 23 | 4 | 163,000 | — | — | |
| Net cash used in investing activities | −216 | −231 | −268 | −226 | −257 | |
| Borrowings on revolving facilities | 1,290 | 1,240 | 905 | 1,120 | 160 | |
| Payments on revolving facilities | −1,295 | −1,415 | −1,070 | −835 | 0 | |
| Proceeds from term loans, net of issuance costs | 0 | 1,880 | 2,092 | 0 | 0 | |
| Payments on term loans | −11 | −2,092 | −2,114 | 0 | 0 | |
| Payment on senior notes, including call premium | 0 | −1,238 | 0 | 0 | — | |
| Proceeds from senior notes, net of issuance costs | 0 | 1,177 | 0 | 0 | — | |
| Borrowings of other debt | 101 | 25 | 31 | 26 | 33 | |
| Principal payments on other debt | −34 | −65 | −47 | −36 | −40 | |
| Dividends paid to common stockholders | −31 | −65 | −64 | −65 | −51 | |
| Repurchase of common stock | −100 | −38 | −13 | −196 | −79 | |
| Decrease in overdrafts | −9 | −4 | −2 | −10 | 42 | |
| Proceeds from issuance of non-controlling interests | 16 | 16 | 23 | 10 | 21 | |
| Distributions to and purchases of non-controlling interests | −90 | −60 | −64 | −43 | −73 | |
| Purchase of membership interests of Concentra Group Holdings Parent | 0 | 0 | −6 | −6 | −661 | |
| Proceeds from Concentra initial public offering | 0 | 511 | 0 | 0 | — | |
| Cash transferred to Concentra at separation | 0 | −182 | 0 | 0 | — | |
| Net cash used in financing activities | −163 | −311 | −327 | −35 | −647 | |
| Net decrease in cash and cash equivalents | −33 | −24 | −14 | 24 | −503 | |
| Cash paid for interest, excluding amounts received of $82,818 and $68,069 under the interest rate cap contract for the years ended December 31, 2023 and 2024, respectively. | 121 | 256 | 272 | 183 | 132 | |
| Cash paid for taxes | 26 | 133 | 89 | 32 | 181 | |
| Liabilities for purchases of property and equipment | 36 | 22 | 18 | 52 | 23 |